SCHEMBL25826013

SCHEMBL25826013

Cc1cccc(Nc2ccc(NC(=O)c3ccc(Nc4ccnc5ccc(N6CCOCC6)cc45)cn3)cc2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPKAPK2 P49137 7/20 0.51
MAPT P10636 4/20 0.50
ALDH1A1 P00352 3/20 0.50
RAB9A P51151 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
SLC2A1 P11166 1/20 0.50
MAPK10 P53779 2/20 0.49
DGAT1 O75907 1/20 0.47
NPC1 O15118 1/20 0.46
LMNA P02545 2/20 0.44
MEN1 O00255 1/20 0.44
GAA P10253 1/20 0.44
MC4R P32245 1/20 0.44
HTT P42858 1/20 0.44
KMT2A Q03164 1/20 0.44
PTK2B Q14289 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
DNMT1 P26358 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23999785 0.90 MAPT (0.54) MAPKAPK2MAPTALDH1A1RAB9ASMN1; SMN2
SCHEMBL30180392 0.90 MAPT (0.54) MAPKAPK2MAPTALDH1A1RAB9ASMN1; SMN2
SCHEMBL24006299 0.83 DNMT1 (0.56) MAPKAPK2MAPTRAB9ASMN1; SMN2SLC2A1
SCHEMBL30180296 0.83 MAPT (0.48) MAPKAPK2MAPTALDH1A1RAB9ASMN1; SMN2
SCHEMBL23999596 0.83 MAPT (0.48) MAPKAPK2MAPTALDH1A1RAB9ASMN1; SMN2
SCHEMBL23999911 0.82 MAPKAPK2 (0.57) MAPKAPK2MAPTALDH1A1RAB9ASMN1; SMN2
SCHEMBL23999914 0.81 MAPKAPK2 (0.55) MAPKAPK2MAPTALDH1A1RAB9ASMN1; SMN2
SCHEMBL24005997 0.80 MAPKAPK2 (0.47) MAPKAPK2MAPTRAB9ASMN1; SMN2SLC2A1
SCHEMBL25825681 0.80 MAPT (0.56) MAPTALDH1A1RAB9ASMN1; SMN2NPC1
SCHEMBL25826014 0.79 MAPKAPK2 (0.47) MAPKAPK2MAPTALDH1A1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230183226-A1 AKT3 MODULATORS Georgiamune Inc. 2023-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183226-A1 AKT3 MODULATORS AKT3, AKT2, MTOR MAPKAPK2 138/4885MAPT 3999/4885ALDH1A1 4541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.